Saturday 17 October 2026
Export OGN’s income statement to Excel — free account
Organon & Co.
OGN Healthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
13.76
0.00
0.00%
Follow OGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 5 | 5 | 5 |
| 71.62% | 30.56% | 34.05% | 24.04% | ||
| 3.81% | 1.44% | 1.88% | 1.57% | ||
ROIC |
8.30% | 5.84% | 6.18% | 6.11% | |
Return on Tangible Assets |
15.13% | 5.73% | 6.63% | 5.53% | |
Average Days of Receivables |
85.96 | 78.16 | 81.97 | 88.88 | |
Free Cash Flow per Share |
2.40 | 1.60 | 2.63 | 1.77 | |
Free Cash Flow |
624.00 | 415.00 | 684.00 | 464.00 | |
Capital Expenditures |
(325.00) | (285.00) | (166.00) | (273.00) | |
| Other line items | |||||
Cash ROIC |
6.00% | 4.16% | 6.46% | 4.34% | |
Accounts Receivable Turnover |
3.98 | 4.62 | 4.34 | 4.12 | |
Accounts Payable Turnover |
2.62 | 2.76 | 2.92 | 2.74 | |
Inventory Turnover |
1.97 | 2.13 | 2.13 | 2.07 | |
Average Days of Payables |
138.37 | 119.70 | 123.38 | 132.33 | |
Days of Inventory on Hand |
191.71 | 176.78 | 172.33 | 170.10 | |
Tax Rate |
(0.29) | (0.56) | (0.54) | (0.57) | |
Research and Development Expense of Revenue |
6.43% | 5.89% | 5.89% | 5.84% | |
Selling, General and Administrative Expense of Revenue |
27.90% | 27.69% | 27.99% | 27.84% | |
Share Based Compensation of Revenue |
1.52% | 1.24% | 1.17% | 1.22% | |
Interest Coverage |
2.34 | 1.63 | 1.68 | 1.76 | |
Operating CF/Net income |
1.89 | 3.74 | 3.46 | 3.53 | |
Depreciation/Fixed assets |
0.27 | 0.47 | 0.47 | 0.46 | |
Capex/Depreciation |
(0.94) | (0.47) | (0.28) | (0.47) | |
Revenue per Share |
24.24 | 23.95 | 23.67 | 23.33 | |
Operating CF per Share |
3.65 | 2.70 | 3.26 | 2.81 | |
Capex per Share |
(1.25) | (1.10) | (0.64) | (1.04) | |
Capex to Sales |
0.05 | 0.05 | 0.03 | 0.04 |
Columns are period end dates